Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8810
Title: | Open, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study | Authors: | Eskiyurt, Nurten İrdesel, Jale Sepici, Vesile Uğurlu, Hatice Kirazlı, Yeşim Ardıç, Füsun Bütün, Bülent Akyüz, Gülseren Cerrahoğlu, Lale Şendur, Ömer Faruk |
Keywords: | Bisphosphonate Ibandronate Patient preference Postmenopausal osteoporosis alendronic acid angiotensin II antagonist anilide beta adrenergic receptor blocking agent calcium dihydropyridine derivative dipeptidyl carboxypeptidase inhibitor diuretic agent hydroxymethylglutaryl coenzyme A reductase inhibitor ibandronic acid risedronic acid salicylic acid salicylic acid derivative serotonin uptake inhibitor vitamin D vitamin D derivative abdominal pain adult aged article Candidate Identification Questionnaire connective tissue disease drug efficacy drug intoxication drug safety drug substitution drug tolerability drug withdrawal dyspepsia female gastrointestinal disease gastrointestinal symptom hernia human infection infestation injury lung embolism major clinical study metabolic disorder multicenter study musculoskeletal disease nausea nutritional disorder open study Osteoporosis Patient Satisfaction Questionnaire patient compliance patient preference patient satisfaction postmenopause osteoporosis prospective study quality of life questionnaire scoring system screening test stomach upset treatment duration treatment outcome Turkey (republic) |
Publisher: | Galenos Yayincilik, | Abstract: | Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (?80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. | URI: | https://hdl.handle.net/11499/8810 https://doi.org/10.4274/tod.29491 |
ISSN: | 2146-3816 |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
aeaa33cc-5274-4071-8353-c63113733bff.pdf | 593.14 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
1
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
1
checked on Nov 21, 2024
Page view(s)
46
checked on Aug 24, 2024
Download(s)
22
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.